

Substitute for form 1449B/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

October 30, 2007

(Use several sheets if necessary)

O I P E

IAP22

NOV 02 2007

PATENT & TRADEMARK OFFICE

ATTORNEY DOCKET NO.
0975.1005-036APPLICATION NO.
10/665,971FIRST NAMED INVENTOR
Junming LeFILING DATE
September 19, 2003EXAMINER
Phillip GambelCONFIRMATION NO.
5342GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA7	5,506,265	4/9/1996	Blitstein-Willinger

EXAMINER

DATE CONSIDERED

Substitute for form 1449B/PTO		ATTORNEY DOCKET NO. 0975.1005-036	APPLICATION NO. 10/665,971	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Junming Le		FILING DATE September 19, 2003
LISTING OF REFERENCES October 30, 2007 (Use several sheets if necessary)		EXAMINER Phillip Gambil	CONFIRMATION NO. 5342	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR12	Bard, F. <i>et al.</i> , "Peripherally Administered Antibodies Against Amyloid β -Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," <i>Nat. Medicine</i> , 6(8): 916-919 (2000).	
AS12	Borrebaeck, C.A.K. (ed.), <i>Antibody Engineering</i> , 2nd Edition, Pub. Oxford University Press, p. 291 (1995).	
AT12	Brok, H.P.M. <i>et al.</i> , "Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody," <i>J. Immunol.</i> , 6554-6563 (2002).	
AU12	Cornillie, F. <i>et al.</i> , "Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease," <i>Aliment. Pharmacol. Ther.</i> , 15: 463-473.	
AV12	Fong, Y. <i>et al.</i> , "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).	
AW12	Geysen, H.M. <i>et al.</i> , "A Synthetic Strategy for Epitope Mapping," <i>In Proc. Tenth Amer. Peptide Symposium</i> , pp. 519-523 (Garland R. Marshall, ed. 1987).	
AX12	Goh, C., "Tumor Necrosis Factors in Clinical Practice," <i>Ann. Acad. Med. Singapore</i> , 19(2): 235-239 (1990).	
AY12	Herve, P. <i>et al.</i> , "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," <i>Lymphoma Res.</i> 9:591 (1990). (Abstract No. 3.25).	
AZ12	Kawasaki, H. <i>et al.</i> , "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infect. Immun.</i> , 57(10):3131-3135 (1989).	
AR13	Socher, S. <i>et al.</i> , "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell surface receptor," <i>Proc. Natl. Acad. Sci., USA</i> , 84: 8829-8833 (1987).	
AS13	Von Asmuth, E.J.U. <i>et al.</i> , "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).	
AT13	Yan, L. <i>et al.</i> , "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha," <i>Chinese J. Biotech.</i> , 7(2): 121-126 (1991).	

EXAMINER	DATE CONSIDERED
----------	-----------------